Tailoring treatment for metastatic hormone-sensitive prostate cancer
Earn accreditation points
Finish 5 case(s) answer 10 question(s) and Earn 1 credit.Continue
New data for patients with mHSPC are paving the way for a more personalised treatment approach. Both men with metastases at first presentation (synchronous) and patients who received local therapy before detection of metastases (metachronous) are addressed.